Barber et al., 2023
ACT-AD Phase 2 Trial Fosgonimeton's Phase 2 ACT-AD trial in Alzheimer's patients fails its primary endpoint
Kee and Hong also investigated these effects, confirming arctigenin (2, 10, and 50 M) reductions on histamine, RNA expression of chemokines macrophage inflammatory protein (MIP)-1, MIP-1, macrophage inflammatory protein (MCP-1), and Regulated Upon Activation, Normally T-Expressed, And Presumably Secreted (RANTES) and pro-inflammatory cytokines, including IL-1, IL-6, IL-8, and TNF-, and protein expression of p-ERK/ERK, p-JNK/JNK, p-p38/p38 and NFB phosphorylation in HMC-1 mast cells [85]
However, there was no statistically significant difference in the risk of obstructive sleep apnea between tirzepatide and semaglutide users (p=.1664)